GlaxoSmithKline's investigational Lp-PLA 2 inhibitor darapladib has failed in a second Phase III study, SOLID-TIMI 52, all but extinguishing any hopes for the product.
GlaxoSmithKline's investigational Lp-PLA 2 inhibitor darapladib has failed in a second Phase III study, SOLID-TIMI 52, all but extinguishing any hopes for the product.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.
